OpenAI acquires Orchestra Bio to link research with drug programs
OpenAI has acquired Orchestra Bio, a platform where people and agents coordinate drug-development studies, campaigns and dependencies. Its technology will join Rosalind, GPT-Rosalind and Rosalind Workbench, extending OpenAI’s life-sciences offering from scientific reasoning and experiment planning into program execution. The aim is to identify delays and connect research decisions across biopharma teams.